

# Chronic Kidney Disease

@ckd\_ce on Twitter



High-Target HDF Convective Dose Achieved in Most Patients in a 6-Month Intermediary Analysis of the CONVINCe RCT











9b) See 📌@NephJC critical discussion #visualabstract by @nephvishnoi <https://t.co/ZudY42TwXd> [pic.twitter.com/CdZZQpvPXK](https://pic.twitter.com/CdZZQpvPXK)

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)

10b) The correct answer is C—truly high! This was supported by an earlier meta-analysis that showed a survival benefit with #HDF when a convection volume was delivered at that dose or higher.

 <https://t.co/F3NNEXb5A3>

— @CKD\_ce (@ckd\_ce) January 17, 2024

12) But, is 23L/session an achievable goal?

This follow-on analysis, by the #CONVINCE authors, aimed to see if at 3 & 6 months of follow-up, how many pts managed to achieve the convective target. <https://t.co/XnrY0zQ5Qa> [pic.twitter.com/WcCqD8xeuf](https://pic.twitter.com/WcCqD8xeuf)

— @CKD\_ce (@ckd\_ce) January 17, 2024





## 16) Methods

📊 Calculated proportion of pts who achieved a convection vol  $\geq 23L$  ( $\pm 1L$ ) at each of their first 3 scheduled visits

📝 Narrative synthesis on clinical notes justification why pts missed high-dose convective vol 🎯

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)



20) Pts who missed the high-dose HDF target on  $\geq 2$  visits:

▾ extracorporeal blood flow rate (335 [44] ml/min vs. 372 [54] ml/min)

♀ Women 53% vs 35%, P=0.029

☞ diabetes 51% vs 32%, P=0.015

⚖️! No differences in vascular access and dialysis session duration [pic.twitter.com/NkEsoThvMF](https://pic.twitter.com/NkEsoThvMF)

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)

21b) Comparing to other HDF literature:

◆ 2 studies included a relatively young patient population with low CVD history

◆ Only extracorporeal blood flow rate & treatment time were previously associated with achieving adequate HDF volume targets. [pic.twitter.com/9VJPRwFIK2](https://pic.twitter.com/9VJPRwFIK2)

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)

23) To recap the CONVINCe meta-analysis, take a look at this beautiful [#visualabstract](#) by [@hellokidneyMD](#)

Are you CONVINCEd to adopt HDF? [pic.twitter.com/yIEd8ExF7e](https://pic.twitter.com/yIEd8ExF7e)

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)

24b) It's b, decrease in all-cause mortality. [#ESHOL](#) trial gave hope of lower CV mortality (HR 0.67, 95% CI, 0.44-1.02)

☞ [#CONVINCE](#): only overall survival was statistically significant (HR 0.77; 95%CI, 0.65 to 0.93), not CV mortality.

🔓 ESHOL trial: <https://t.co/6pmlerlvj>

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)



26b) Special thanks also to [@ghobby](#) and [@brian\\_rifkin](#) for help with this tweetorial and to [@ISNKidneyCare](#) for the opportunity [pic.twitter.com/L4kXFIUxMZ](https://pic.twitter.com/L4kXFIUxMZ)

— @CKD\_ce (@ckd\_ce) [January 17, 2024](#)















